Zura Bio Limited · NASDAQ:ZURA
Zura Bio — Jefferies Global Healthcare Conference 2025
21 slides from Zura Bio's conference presentation, Jun 4, 2025
Slide 1: Advancing Dual-Pathway Biologic Candidates in Autoimmune and Inflammatory Diseases
Advancing Dual-Pathway Biologic Candidates Addressing Unmet Needs in Autoimmune and Inflammatory Diseases Jefferies Global Healthcare Conference 2025 Wednesday, June 4, 2025 New York City #JefferiesHealthcare Nasdaq Ticker: ZURA
Slide 2: Forward Looking Statements Disclaimer
©2025 Zura Bio Ltd. 2 Forward Looking Statements Disclaimer This communication includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “antic
Slide 3: From Foundation to Execution: A Biotech Built for Impact
©2025 Zura Bio Ltd. From Foundation to Execution: A Biotech Built for Impact Sources: Zura Bio press releases and SEC filings Acronyms: CEO, Chief Executive Officer; CMO, Chief Medical Officer; HS, hidradenitis suppurativa; SSc, systemic sclerosis 3 Nasdaq: ZURA 2022 In-licensed crebankitug (ZB-168)
Slide 4: Pipeline of Novel Dual-Pathway Biology Designed to Address I&I Diseases
©2025 Zura Bio Ltd. Pipeline of Novel Dual-Pathway Biology Designed to Meaningfully Address Outcomes in I&I Diseases Sources: Clinical study reports Acronyms: BAFF, B cell activating factor; Anti-BAFF Ab, anti-B cell activating factor antibody; EGFR, epidermal growth factor receptor; GM-CSF, granulo
Slide 5: Transformative Opportunity for Tibulizumab
Transformative Opportunity for Tibulizumab Tibulizumab | ZB-106 | Anti-BAFF and IL-17 Tibulizumab, is an investigational agent. Its efficacy and safety have not been established or approved by any regulatory agency worldwide.
Slide 6: Tibulizumab Targets IL-17A, BAFF, or Both
©2025 Zura Bio Ltd. Tibulizumab Targets IL-17A, BAFF, or Both Acronyms: Ab, antibody; BAFF, B cell activating factor; BAFF 60-mer, high-order oligomeric form of BAFF; BAFFR, B cell activating factor receptor; BCMA, B cell maturation antigen; IL, interleukin; IL-17A, interleukin-17A; IL-17F, interleu
Slide 7: An Overview of Tibulizumab
An Overview of Tibulizumab Tibulizumab | ZB-106 | Anti-BAFF and IL-17 Tibulizumab, is an investigational agent. Its efficacy and safety have not been established or approved by any regulatory agency worldwide.
Slide 8: Systemic Sclerosis Is a Multi-Organ Disease With No Comprehensive Treatment
©2025 Zura Bio Ltd. Systemic Sclerosis Is a Multi-Organ Disease With No Comprehensive Treatment* 8 Systemic Sclerosis Is a Rare and Life-Threatening Disease ~300,000 people with SSc in US, EU and Japan1 Zero drugs are currently approved that target the totality of SSc * (*) Two therapies are approve
Slide 9: Separately Inhibiting IL-17A or BAFF Has Shown Efficacy in Placebo-Controlled Trials for SSc
©2025 Zura Bio Ltd. Separately Inhibiting IL-17A or BAFF Has Shown Efficacy in Placebo-Controlled Trials for SSc Sources: 1 Fukasawa T et al., Annals of the Rheumatic Diseases (doi:10.1136/annrheumdis-2022-eular.2519); 2 Gordon JK et al., Arthritis & Rheumatology (doi:10.1002/art.40358) Acronyms: BA
Slide 10: TibuSURE Phase 2 Trial Design in SSc
©2025 Zura Bio Ltd. 10 Efficacy Period (24 weeks) Baseline image HRCT HRCT OLE (28 weeks) 1:1 R tibulizumab tibulizumab (n = 40) placebo* (n = 40) n = 80 participants (weeks) 0 2 4 8 12 16 20 24 28 32 36 40 44 48 52 HRCT RANDOMIZED PHASE 2 TRIAL (mRSS and qHRCT) with an OPEN-LABEL EXTENSION KEY INCL
Slide 11: An Overview of Hidradenitis Suppurativa
Nasdaq: ZURA | www.zurabio.com An Overview of Hidradenitis Suppurativa ©2025 Zura Bio Ltd. 11 ~50% of patients report dissatisfaction with their treatment6-7 Average time to diagnosis is 7 years ~300K people living with HS in the U.S. DISEASE OVERVIEW CLINICAL OPPORTUNITY 6 Sources: 1 Moran B et al.
Slide 12: Advancing Treatment in Moderate-to-Severe HS: Exploring B-Cell Inhibition
©2025 Zura Bio Ltd. Advancing Treatment in Moderate-to-Severe HS: Exploring B-Cell Inhibition B-cell inhibition offers a mechanistically distinct approach that may address unmet needs in HS management. Biologics approved for HS show comparable HiSCR75 efficacy, though their use may be limited by box
Slide 13: The Potential for Setting a New Standard in I&I Demonstrated in VEGA UC Study
©2025 Zura Bio Ltd. The Potential for Setting a New Standard in I&I Demonstrated in VEGA UC Study (*) HS data are illustrative. Combination results are hypothetical and not based on clinical trial data. For informational purposes only. Sources: 1 Feagan B et al., The Lancet Gastroenterology & Hepato
Slide 14: Strong Binding Affinity May Lead to Improved Target Engagement and Clinical Outcomes
©2025 Zura Bio Ltd. Strong Binding Affinity May Lead to Improved Target Engagement and Clinical Outcomes (*) Tibulizumab was engineered from Taltz® (ixekizumab) Sources: Taltz® prescribing information, Lilly USA LLC (https://taltz.lilly.com/hcp/moa-il17a-igg4) Acronyms: IgG4, immunoglobulin G4; IL-1
Slide 15: Preliminary Real-World Evidence Suggests Ixekizumab May Offer Benefit in TNFα-Experienced HS Patients
©2025 Zura Bio Ltd. Preliminary Real-World Evidence Suggests Ixekizumab May Offer Clinical Benefit in TNFα-Experienced HS Patients Sources: Hilbring C et al., Dermatologic Therapy (doi:10.1155/dth/5597039) Acronyms: DLQI, Dermatology Life Quality Index; HS, hidradenitis suppurativa; IHS4, Internatio
Slide 16: Mechanistic Innovation Enabled Psoriasis Market Expansion; HS May Offer Similar Opportunity
©2025 Zura Bio Ltd. Mechanistic Innovation Enabled Psoriasis Market Expansion; HS May Offer a Similar Opportunity (*) The dates shown indicate FDA-approval years for a representative, non-comprehensive list of therapies and are intended for illustrative purposes. Sources: Evaluate Pharma; CenterWatc
Slide 17: Tibulizumab Offers Encouraging Combination of Attributes for HS
©2025 Zura Bio Ltd. Tibulizumab Offers Encouraging Combination of Attributes for HS Sources: 1 van Straalen KR et al., Journal of Investigative Dermatology (doi:10.1016/j.jaci.2022.02.003); 2 Malvaso D et al., Pharmaceutics (doi:10.3390/pharmaceutics15102450); 3 US Food and Drug Administration, Bimz
Slide 18: TibuSHIELD Phase 2 Trial Design in HS
©2025 Zura Bio Ltd. 18 Efficacy Period (16 weeks) OLE (16 weeks) 1:1:1 R tibulizumab (n = 60) high dose n = ~180 participants placebo (n = 60) (weeks) 20 24 28 32 DOUBLE BLIND, PLACEBO-CONTROLLED, 16-WEEK TRIAL with an OPEN-LABEL EXTENSION tibulizumab (n = 60) low dose tibulizumab low dose 0 2 4 8 1
Slide 19: Tibulizumab Advancing in SSc and HS: Phase Data Expected 2H 2026
©2025 Zura Bio Ltd. Tibulizumab Advancing in SSc and HS: Phase 2 Data Expected 2H 2026* (*) The timing of regulatory and clinical-trial milestones is subject to change and may require further interactions with the FDA. (**) Eligible participants from TibuSURE (SSc) and TibuSHIELD(HS) can transition
Slide 20: Tibulizumab Summary
©2025 Zura Bio Ltd. Tibulizumab is currently being evaluated in two ongoing Phase 2 clinical trials: TibuSURE for adults with systemic sclerosis and TibuSHIELD for adults with hidradenitis suppurativa The strategy follows validated pathways with the potential for improved outcomes, supported by rela
Slide 21: Thank You
Nasdaq: ZURA | www.zurabio.com Thank You
Zura Bio — Jefferies Global Healthcare Conference 2025 on 6ix